The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.

Mark Daniels, 83, says CAR T-cell therapy and strong support helped him overcome lymphoma twice and return to the ...

In part 4, the author reflects on her mother’s silent strength and unwavering love during her cancer journey, as she cared ...

Tamron Little was diagnosed with peritoneal mesothelioma in 2007 as a 21-year-old new mother. Catch up on Tamron's blogs here ...

Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World ...

Two glioblastoma patients treated with Temferon have lived 3 years post-surgery; one had no progression, the other stabilized ...

Valarie Traynham, a cancer thriver and patient advocate, imparts advice and discusses survivorship after a cancer diagnosis.

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care ...

Waldenström macroglobulinemia is often slow growing, with a 78% five-year survival rate, but chronic conditions can affect ...

Three of five patients with advanced colorectal cancer responded to leronlimab, including one complete response lasting five years, according to new data.